Gurruchaga Sotés, I.; Alves, A.N.; Arregui, S.V.; Santander Lobera, C. Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC). Current Oncology 2021, 28, 2346–2350, doi:10.3390/curroncol28040216.
Gurruchaga Sotés, I.; Alves, A.N.; Arregui, S.V.; Santander Lobera, C. Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC). Current Oncology 2021, 28, 2346–2350, doi:10.3390/curroncol28040216.
Gurruchaga Sotés, I.; Alves, A.N.; Arregui, S.V.; Santander Lobera, C. Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC). Current Oncology 2021, 28, 2346–2350, doi:10.3390/curroncol28040216.
Gurruchaga Sotés, I.; Alves, A.N.; Arregui, S.V.; Santander Lobera, C. Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC). Current Oncology 2021, 28, 2346–2350, doi:10.3390/curroncol28040216.
Abstract
In clinical guidelines, such as National Comprehensive Cancer Network guidelines, it is embodied as first therapeutic option the combination of erlotinib and bevacizumab, based on a small clinical trial which included patients with HLRCC. With this case report we bring out another treatment option, not described before, with extraordinary results based on the combination of a check-point inhibitor and a tyrosine-kinase inhibitor, based on theoretical tumor immunogenic environment.
Keywords
Hereditary Leyomiomatosis and Renal Cell Cancer; Pembrolizumab; Axitinib
Subject
Medicine and Pharmacology, Immunology and Allergy
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.